Anxo Pharmaceutical Co (ROCO:6677) Debt-to-Equity : 0.72 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Anxo Pharmaceutical Co Debt-to-Equity?

Anxo Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$288.1 Mil. Anxo Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$499.7 Mil. Anxo Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$1,089.5 Mil. Anxo Pharmaceutical Co's debt to equity for the quarter that ended in Dec. 2023 was 0.72.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Anxo Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

ROCO:6677' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.72 Med: 1.32 Max: 1.97
Current: 0.72

During the past 11 years, the highest Debt-to-Equity Ratio of Anxo Pharmaceutical Co was 1.97. The lowest was 0.72. And the median was 1.32.

ROCO:6677's Debt-to-Equity is ranked worse than
77.33% of 847 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs ROCO:6677: 0.72

Anxo Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Anxo Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anxo Pharmaceutical Co Debt-to-Equity Chart

Anxo Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.58

1.25

1.21

1.23

0.72

Anxo Pharmaceutical Co Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial													1.21	1.26	1.23	1.20	0.72

Competitive Comparison of Anxo Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anxo Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Anxo Pharmaceutical Co's Debt-to-Equity falls into.

Anxo Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Anxo Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(288.145	+	499.695)	/	1089.489
	=	0.72

Anxo Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(288.145	+	499.695)	/	1089.489
	=	0.72

Anxo Pharmaceutical Co (ROCO:6677) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Anxo Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Anxo Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Anxo Pharmaceutical Co (ROCO:6677) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN

Website

http://www.anxo.com.tw

Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.

Anxo Pharmaceutical Co (ROCO:6677) Headlines

No Headlines